Smartinhaler maker Adherium has announced the appointment of former MicroDose Therapeutx co-founder Scott Fleming as Senior VP of Business Development, Europe, effective immediately. Fleming replaces John Tarplee who left the company at the end of 2016 “to pursue a new venture.”
After the sale of MicroDose Therapeutx to Teva in 2013, Fleming served as Senior Director, Global Commercial Respiratory and Senior Director, Global Respiratory Marketing at Teva. As Global Brand Lead for eConnectivity of Teva’s respiratory products, he led the commercial strategy for connected inhalers, including those using MicroDose’s digital technology.
Fleming said, “Having first collaborated with Adherium nine years ago, working to enable data capture to the cloud, it is great to now be joining the team. I have watched Adherium’s technology grow to play a vital role providing key clinical data proofs for the digital drug delivery industry. I look forward to using my experience in this space to build on Adherium’s capabilities, reaching more patients and improving adherence and outcomes.”
Adherium CEO Garth Sutherland commented, “Bringing a pioneer of the digital health movement into our business is an exciting development as we continue to build our commercial capabilities, particularly in Europe. Scott’s 25 years’ experience in the field, combined with Adherium’s leading expertise will ensure a compelling proposition for partners and customers.”
The company said that it will base its European operation in Amsterdam, the Netherlands, and Fleming will work from that location.
Read the Adherium press release.
